Background: The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5- fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in patients with heavily pretreated recurrent epithelial ovarian cancer. Methods: Clinical data were reviewed in 29 patients who received FOLFOX-4 as more than third-line chemotherapy, consisting of 85 mg/m2 of oxaliplatin, 200 mg/m2 of leucovorin, and bolus 400 mg/m2 on day 1 of 5-fluorouracil, followed by a 22-h infusion of 600 mg/m2 of 5-fluorouracil for 2 consecutive days every 3 weeks. We also compared the efficacy and toxicity of FOLFOX-4 with that of topotecan, a standard treatment, given at a dosage of 1.5 mg/m2 every three weeks in 26 patients. Results: The median age of enrolled patients was 60 years (range 33 to 85). A median of 4 cycles (range 1–17) of FOLFOX-4 were administered. Complete response and partial response were observed in one (3.5%) and 5 (17.2.2%) patients, respectively, while stable disease was reported in 8 (27.6%) patients. Among all patients, grade 3–4 anemia, neutropenia, and thrombocytopenia were observed in 0 (0%), 5 (17.2%), and 3 (10.3%) cases, respectively. Grade 3–4 fatigue was recorded in one (3.4%) patient and diarrhea in 2 (6.9%). Median PFS and OS were 2.8 months [95% confidence interval (CI) 1.7–4.9] and 6.2months (95% CI 2.4–14.6), respectively. No significant differences in terms of efficacy and toxicity were observed between patients receiving FOLFOX-4 and those treated with topotecan. Conclusions: The FOLFOX-4 regimen would seem to obtain similar survival rates to those of standard therapy with topotecan in platinum-resistant ovarian cancer. Further randomized trials are warranted to confirm our findings.

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer / Conteduca, Vincenza; Gurioli, Giorgia; Rossi, Lorena; Scarpi, Emanuela; Lolli, Cristian; Schepisi, Giuseppe; Farolfi, Alberto; De Lisi, Delia; Gallà, Valentina; Luca Burgio, Salvatore; Menna, Cecilia; Amadori, Andrea; Losi, Lorena; Amadori, Dino; Costi, Maria Paola; De Giorgi, Ugo. - In: BMC CANCER. - ISSN 1471-2407. - 18:1(2018), pp. 1-9. [10.1186/s12885-018-5180-1]

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Lorena Losi;Maria Paola Costi;
2018

Abstract

Background: The purpose of this study was to evaluate the clinical impact of oxaliplatin, leucovorin, and 5- fluorouracil (FOLFOX-4) chemotherapy in terms of the response rate, progression-free/overall survival (PFS/OS) and safety profile in patients with heavily pretreated recurrent epithelial ovarian cancer. Methods: Clinical data were reviewed in 29 patients who received FOLFOX-4 as more than third-line chemotherapy, consisting of 85 mg/m2 of oxaliplatin, 200 mg/m2 of leucovorin, and bolus 400 mg/m2 on day 1 of 5-fluorouracil, followed by a 22-h infusion of 600 mg/m2 of 5-fluorouracil for 2 consecutive days every 3 weeks. We also compared the efficacy and toxicity of FOLFOX-4 with that of topotecan, a standard treatment, given at a dosage of 1.5 mg/m2 every three weeks in 26 patients. Results: The median age of enrolled patients was 60 years (range 33 to 85). A median of 4 cycles (range 1–17) of FOLFOX-4 were administered. Complete response and partial response were observed in one (3.5%) and 5 (17.2.2%) patients, respectively, while stable disease was reported in 8 (27.6%) patients. Among all patients, grade 3–4 anemia, neutropenia, and thrombocytopenia were observed in 0 (0%), 5 (17.2%), and 3 (10.3%) cases, respectively. Grade 3–4 fatigue was recorded in one (3.4%) patient and diarrhea in 2 (6.9%). Median PFS and OS were 2.8 months [95% confidence interval (CI) 1.7–4.9] and 6.2months (95% CI 2.4–14.6), respectively. No significant differences in terms of efficacy and toxicity were observed between patients receiving FOLFOX-4 and those treated with topotecan. Conclusions: The FOLFOX-4 regimen would seem to obtain similar survival rates to those of standard therapy with topotecan in platinum-resistant ovarian cancer. Further randomized trials are warranted to confirm our findings.
18
1
1
9
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer / Conteduca, Vincenza; Gurioli, Giorgia; Rossi, Lorena; Scarpi, Emanuela; Lolli, Cristian; Schepisi, Giuseppe; Farolfi, Alberto; De Lisi, Delia; Gallà, Valentina; Luca Burgio, Salvatore; Menna, Cecilia; Amadori, Andrea; Losi, Lorena; Amadori, Dino; Costi, Maria Paola; De Giorgi, Ugo. - In: BMC CANCER. - ISSN 1471-2407. - 18:1(2018), pp. 1-9. [10.1186/s12885-018-5180-1]
Conteduca, Vincenza; Gurioli, Giorgia; Rossi, Lorena; Scarpi, Emanuela; Lolli, Cristian; Schepisi, Giuseppe; Farolfi, Alberto; De Lisi, Delia; Gallà, Valentina; Luca Burgio, Salvatore; Menna, Cecilia; Amadori, Andrea; Losi, Lorena; Amadori, Dino; Costi, Maria Paola; De Giorgi, Ugo
File in questo prodotto:
File Dimensione Formato  
Conteduca_et_al-2018-BMC_Cancer.pdf

accesso aperto

Descrizione: articolo
Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 726.3 kB
Formato Adobe PDF
726.3 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1172760
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact